Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

  1. Dimopoulos, M.
  2. Quach, H.
  3. Mateos, M.-V.
  4. Landgren, O.
  5. Leleu, X.
  6. Siegel, D.
  7. Weisel, K.
  8. Yang, H.
  9. Klippel, Z.
  10. Zahlten-Kumeli, A.
  11. Usmani, S.Z.
Journal:
The Lancet

ISSN: 1474-547X 0140-6736

Year of publication: 2020

Volume: 396

Issue: 10245

Pages: 186-197

Type: Article

DOI: 10.1016/S0140-6736(20)30734-0 GOOGLE SCHOLAR

Sustainable development goals